Locations:
September 15, 2025/Cancer/Podcast

Improving Survivorship for Women with Bladder Cancer

A podcast episode

Bladder cancer is more common in men than women yet it tends to present more aggressively and at later stages in women. The treatment paradigm has evolved in recent years.

"Historically speaking over the last 50 years, it's always been chemotherapy followed by consolidative surgery, so removal of your bladder in women, removal of ovaries, the uterus, you take the ovaries, you take the tubes out, but that's have shifted," says urologic oncologist Laura Bukavina. "We're now focusing more on not only preservation of organs, we're also focusing and shifting our goal to potentially organ preservation in terms of the whole bladder preservation. So, there's a spectrum of saving some organs, preservation of nerves, or potentially doing what's called complete organ preservation or bladder preservation programs."

In a recent episode of Cleveland Clinic’s Cancer Advances podcast, Dr. Bukavina addresses:

- The feasibility of preserving organs such as ovaries and the uterus
- Preserving nerve function to help protect sexual function
- Employing neoadjuvant therapy before surgery to further help with organ and nerve preservation
- Supporting patients with social work, mental health, pelvic floor therapy, and more to address the physical and emotional issues that can accompany bladder cancer and bladder cancer treatment

Click the podcast player above to listen to the episode now, or read on for a short edited excerpt. Check out more Cancer Advances episodes at clevelandclinic.org/podcasts/cancer-advances or wherever you get your podcasts.

Excerpt from the podcast:

Dale Shepard, MD, PhD: When you think about quality of life after treatment, this is a really important area, but it's frequently not addressed. The reality
is patients don't mention it, docs don't talk about it. There's time components.
How do you make it work?

Laura Bukavina, MD, MPH: You talk about it. Talk about it like we're talking about it now. You write about it. You make it acceptable. So, many of these patient organization, patient advocate organizations like BCAN, it's a huge topic that the patients are always talking about. So, patients discussing among themselves will make it acceptable for a patient to ask those questions. They sometimes feel ashamed, scared, uncertain if it's the right question, so making it okay to ask questions about organ preservation and sexual function.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Related Articles

Dr. Anwer and colleagues
November 12, 2026/Cancer/Blood Cancers

FDA Approval of Iberdomide Marks Historic Milestone in Multiple Myeloma

CELMoD therapy receives approval based primarily on measurable residual disease

Dr. Dedousis
November 2, 2026/Cancer/Podcast

Expanding Germline Genetic Testing in Oncology (Podcast)

Are we missing patients?

Dr. Hanlee Chung
October 29, 2026/Cancer/Podcast

Redefining Resectability in Advanced Rectal Cancer (Podcast)

Expanding treatment options for patients with advanced and recurrent rectal cancer

Patient and healthcare providers
October 28, 2026/Cancer/Patient Support

Desire for Preventative Screening is Strong Among People Experiencing Homelessness

Study analyzes creative approaches to support people facing housing insecurity

AI tech
October 26, 2026/Cancer/Innovations

AI Task Force Develops Unified Strategy to Integrate Tech Innovations

Evaluating AI initiatives and their impact on operations and care delivery

DNA test
October 23, 2026/Cancer/News & Insight

Early Genetic Testing Linked to Bilateral Mastectomy in Young BRCA Carriers with Breast Cancer

Study reinforces the importance of genetic testing prior to local therapy decisions

Dr. Arun Singh
October 21, 2026/Cancer

Preserving Vision in Uveal Melanoma (Podcast)

Understanding expanding treatment options and potential advances

Patient and doctor
October 9, 2026/Cancer/News & Insight

First Radioligand Therapy Approved for Metastatic Hormone-Sensitive Prostate Cancer

Adding 177Lu-PSMA-617 to ADT plus an ARPI cut the risk of radiographic progression or mortality by 28%

Ad